← 治験一覧に戻る
冠動脈疾患または末梢動脈疾患における主要心血管イベントの予防のためのリバーロキサバン
基本情報
- NCT ID
- NCT01776424
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 27,395
- 治験依頼者名
- Bayer
概要
The primary objectives of this study are: * To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD); * To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.
対象疾患
Prevention & Control
介入
Rivaroxaban (Xarelto, BAY59-7939)(DRUG)
Rivaroxaban (Xarelto, BAY59-7939)(DRUG)
Aspirin(DRUG)
Aspirin placebo(DRUG)
Rivaroxaban placebo(DRUG)
Pantoprazole(DRUG)
Pantoprazole placebo(DRUG)